Early detection and intervention are key strategies to reduce mortality, increase 3 7 long-term survival and improve the therapeutic effects of hepatocellular carcinoma 3 8 (HCC) patients. Herein, the isobaric tag for relative and absolute quantitation (iTRAQ) 3 9 quantitative proteomic strategy was used to study the secretome in conditioned media 4 0 from HCC cancerous tissues, surrounding noncancerous and distal noncancerous 4 1 tissues to identify diagnostic and prognostic biomarkers for HCC. In total, 22 and 49 4 2 secretory proteins were identified to be dysregulated in the cancerous and surrounding 4 3 noncancerous tissues compared with the distal noncancerous tissues. Among these 4 4
of CA2 on the diagnosis and prognosis of HCC in two additional serum cohorts via 2 2 8 the PRM targeted proteomic method and traditional ELISA assays. The CA2 serum concentration was monitored in 49 HCC patients and 23 healthy 2 3 0 volunteers through PRM. There were 9 identified peptides from CA2 in total, 7 of 2 3 1 which were overlapped in the five 8-plex iTRAQ experiments, and 1 of which had a 2 3 2 mis-cleavage site. Therefore, only 6 peptides from CA2 could be used for the PRM 2 3 3 experiment, and the annotated spectra and detailed PSM information for these 6 2 3 4
identified CA2 peptides were provided in Table S5 and Figure S3 . For the skyline 2 3 5 results, the peak contributions of the individual fragment ions from the unique peptide 2 3 6 was showed in Figure S2B , and the representative quantification information based on 2 3 7 peak areas of the peptides including endogenic and synthetic heavy peptides was 2 3 8 displayed in Figure S2C . The CA2 serum concentration in HCC patients was 2 3 9
remarkably higher than that in normal populations (p < 0.01, 7.01 and 13.72 pg/mL 2 4 0 average serum CA2 in healthy volunteers and HCC patients, respectively). The ( Figure 4A ). These results were consistent with the data from the proteomic studies, indicating that CA2 might be a valuable biomarker for HCC diagnosis. According to our previous study, the serum levels of CA2 were steadily increased 2 4 7 from 3 months to 9 months after radical resection in the patients with short-term 2 4 8 recurrence compared with the patients without recurrence ( Figure S4A ). According to 2 4 9 these data, we expect to find an appropriate time point after radical resection to 2 5 0 predict the recurrence of HCC. The serum samples taken 5 months after surgery were 2 5 1 collected blindly. An ELISA assay was used to analyze the association between the relapsed patients and 65 relapse-free patients. As revealed in Figure 4B , serum CA2 ( Figure 4C ). Furthermore, we repeated this study using the training cohort of 49 HCC 2 6 6 patients and obtained identical results ( Figure S4B ). In addition, we found a strong 2 6 7 negative linear correlation between serum CA2 levels and the recurrence time, indicating that the higher the serum CA2, the shorter the recurrence time ( Figure S4C ).
6 9
These results suggested that the serum CA2 level might be a novel prognostic 2 7 0 biomarker for HCC. As the gold standard for clinical diagnosis and monitoring in HCC, AFP was 2 7 3 remarkably higher in relapsed HCC patients than that in patients without relapse (p < 2 7 4 0.001) ( Figure S4D ). Although the recurrence rate was substantially lower while the 2 7 5
overall survival was remarkably higher in AFP-negative patients than that in metastasis ( Figure S4F ). Therefore, there is an urgent need to identify novel 2 8 0 biomarkers that can predict the recurrence/metastasis in AFP-negative HCC patients. Interestingly, among the AFP-negative HCC patients, the serum concentration of CA2 2 8 2 in relapsed patients was remarkably higher than that in relapse-free patients (p < 0.001) 2 8 3 ( Figure 4D ). Furthermore, in the AFP-negative HCC patients, the recurrence rates 2 8 4
were also higher in patients with high CA2, suggesting the prognostic values of CA2 2 8 5 in AFP-negative patients ( Figure 4E ). The overall survival rate did not show 2 8 6 significant differences between the high-CA2 and low-CA2 groups ( Figure S4G ). According to the above results, we confirmed that CA2 had a prognostic value in 2 8 9
AFP-negative patients. We then jointly considered the CA2 and AFP serum levels. As shown in Figure 4F , when CA2 and serum AFP were considered together, the AUC 2 9 1 reached to 0.803 for the combination of CA2/AFP (AUC of 0.708 for CA2 and 0.765 2 9 2 for AFP), suggesting a clinical values for the combination of these 2 markers. Next, 2 9 3
we further evaluated the prognostic value of CA2/AFP in combination for HCC 2 9 4 patients in the validation cohort. As shown in Figure 4G , the cumulative recurrence 2 9 5 rate in patients in the low-CA2 and AFP-negative group was remarkably lower than 2 9 6 that of patients in the high-CA2 and AFP-positive group. Correspondingly, the overall 2 9 7 survival of patients in the low-CA2 and AFP-negative group was substantially higher To further study molecular mechanisms of CA2 on the prognosis of HCC, we further HCC patients. As revealed in Table S6 , the Pearson's chi-square test has indicated that 3 0 7
higher serum CA2 level was significantly correlated with more tumour number (p = 3 0 8 0.026) and more advanced BCLC stage (p = 0.042), but did not associated with other 3 0 9 clinicopathologic features. These results suggested that CA2 might be a 3 1 0 metastasis/recurrence-related protein in HCC. To investigate the molecular mechanism of extracellular CA2 in HCC 3 1 4 recurrence/metastasis, exogenous recombinant CA2 protein (obtained from Abcam) 3 1 5 was used to examine its influences on the migration and invasion ability of HCC cells 3 1 6
using a trans-well strategy. As shown in Figure 5A , exogenous recombinant CA2 (EMT) is well known to be responsible for tumour metastasis. As shown in Figure 5B , involved molecular mechanisms, the related key markers of EMT were also analyzed. As shown in Figure 5C , the addition of exogenous recombinant CA2 upregulated We also studied the intracellular levels of CA2 in HCC patients. In this experiment, western blot. As revealed in Figure 6A and B, the intracellular CA2 expression was suggesting that intracellular and extracellular CA2 might carry out opposite functions 3 4 5
[42]. However, the involved molecular mechanisms should be further explored. Herein, we applied the iTRAQ-based quantitative proteomic approach to investigate 3 4 8
the secretome of the primary culture of HCC tissues, and identified secreted CA2 as a 3 4 9
diagnostic and prognostic biomarker for HCC. In particular, CA2 showed good
predicative performance in AFP-negative HCC patients, and the combination of CA2 further HCC investigation and for identifying potential serological biomarkers. In total, 293 HCC patients and 23 healthy volunteers were enrolled in the current branch; postoperative pathological examination showed no cancer cells at the cutting 3 7 2 edge; no recurrence/metastasis was found in the ultrasound and CT examination 2 For the proteomic analysis, HCC tissues, surrounding noncancerous tissues and Tissue culture and quality control in vitro 3 9 3
Following surgical operation, the primary tissue specimens were immediately 3 9 4 transferred into PBS on ice and sent to the laboratory within 30 min. The tissues were 3 9 5 then rinsed and cut into 2-3 mm 3 pieces, and extensively washed several times at room 3 9 6
temperature with PBS to eliminate major blood and serum contaminants. Subsequently, the samples were transferred to 10 cm cell culture dishes and incubated The cultured tissues were fixed in 10 % neutral formaldehyde, and paraffin sections The proteomic studies and data analyses were modified from our previously reported The peptide mixture was separated using an offline LC system (Acquity UPLC, Thermo Fisher Scientific, Germany). Next, the peptides were detected by mass The data processing strategy was also carried out according to our previous tolerance was applied for the most confident centroid peak. In Sequest HT, the 4 7 3 quantitative protein ratios were normalized and weighted by the median ratio. In iTRAQ experiment for subsequent analysis. In detail, the raw data was searched by 4 7 9
Proteome Discoverer using Sequest HT search algorithms, and the generated file was iTRAQ experiments could then be obtained directly by grouping. In the same way, a 4 8 2 peptide FDR < 1% and a protein probability > 99.0% were accepted. Millipore, USA). The procedures for serum protein denaturation, reduction, alkylation 5 0 7
and digestion were described above.
0 8
For PRM analysis, the unique peptides for CA2 were synthesized by Fmoc 5 0 9
solid-phase synthesis with isotope-labeled on the carboxyl side of the amino acid 5 1 0 lysine ( 13 C 6 , 15 N 2 ) and purified by HPLC with purity > 99% (Anhui Guoping 5 1 1
Pharmaceutical Co., Ltd, China). The heavy-labeled peptides were mixed and spiked 5 1 2
into the tryptic digests of serum proteins at a concentration of 30 fg/μL. Detailed 5 1 3
information for the unique CA2 peptides were displayed in Table S5 . The unique 5 1 4 peptide for CA2 should preferably have a narrow, symmetrical chromatographic peak, without any modification, and not elute at the beginning or end time. The PRM analyses were also performed on a mass spectrometer (Q Exactive Plus, 5 1 8
Thermo Fisher Scientific, Germany). LC separation was executed with a trap column of ± 2. In addition, a normalized collision energy of 27% was used for ion dissociation, corresponding retention times of precursor peptides of interest were displayed in 5 2 9 Table S5 .
The PRM raw data was analyzed with Skyline software (version 4.2, University of 5 3 1
Washington, USA), and a 5-minute window was used in the Skyline software. The 5 3 2 sum of peak areas of the 5 most intense product ions was considered for protein 5 3 3
quantification. Some ions needed to be excluded: for example, those ions that did not 5 3 4
match the retention time of other monitored ions, or that showed interference signals, 5 3 5
or that gave intense signals at other retention time. The serum levels of CA2 in HCC patients were analyzed using an ELISA assay kit Western blotting was performed according to a previous publication [44] . Briefly, 
